Peptides of syndecan-1 for inhibition of cancer
OwnerAlan Rapraeger, DeannaLee Beauvaisinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel peptide from the extracellular domain of syndecan-1 that inhibits migration, metastasis, survival and proliferation of cancer cells.
Claims31
An isolated and purified peptide or polypeptide segment consisting of 5-240 amino acid residues and comprising at least 5 contiguous residues of SEQ ID NO:4.
A nucleic acid encoding an isolated and purified peptide or polypeptide consisting of 5-240 amino acid residues and comprising at least 5 contiguous residues of SEQ ID NO:4 or SEQ ID NO:8 or SEQ ID NO:9.
-13. (canceled)
A method of inhibiting interaction of αvβ3 or αvβ5 integrin with syndecan-1 comprising contacting a αvβ3or αvβ5 integrin molecule with a peptide or polypeptide consisting of 5-240 amino acid residues and comprising at least 5 contiguous residues of SEQ ID NO:4 or SEQ ID NO:8 or SEQ ID NO:9.
A method of inhibiting αvβ3 or αvβ5 integrin activation by syndecan-1 comprising contacting a cell expressing an αvβ3 or αvβ5 integrin molecule with a peptide or polypeptide consisting of 5-240 amino acid residues and comprising at least 5 contiguous residues of SEQ ID NO:4 or SEQ ID NO:8 or SEQ ID NO:9.
A method of inhibiting a cancer cell expressing αvβ3 or or αvβ5 integrin comprising contacting a cell expressing an αvβ3 or or αvβ5 integrin molecule with a peptide or polypeptide consisting of 5-240 amino acid residues and comprising at least 5 contiguous residues of SEQ ID NO:4 or SEQ ID NO:8 or SEQ ID NO:9.
A method of treating a subject with a cancer, cells of which express αvβ3or or αvβ5 integrin, comprising contacting a cell expressing an αvβ3 or or αvβ5 integrin molecule with a peptide or polypeptide consisting of 5-240 amino acid residues and comprising at least 5 contiguous residues of SEQ ID NO:4 or SEQ ID NO:8 or SEQ ID NO:9.
-35. (canceled)
Dependencies are inferred from the claim text.